Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Central Nervous System Neoplasms 12Astrocytoma 10Brain Neoplasms 9Lymphoma, Non-Hodgkin 8Gliosarcoma 8Glioblastoma 8Oligodendroglioma 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Glioma 7Lymphoma, Mantle-Cell 6Lymphoma, Follicular 5Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Ependymoma 4Recurrence 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Neuroectodermal Tumors, Primitive 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, B-Cell 2Unspecified Adult Solid Tumor, Protocol Specific 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Pediatric Brain Tumor 1

Interventions

Cyclophosphamide 52Cytarabine 49fludarabine phosphate 38fludarabine 32Filgrastim 30Etoposide 23Rituximab 19Azacitidine 17Whole-Body Irradiation 16Tacrolimus 14Peripheral Blood Stem Cell Transplantation 13Granulocyte Colony-Stimulating Factor 13Decitabine 13Clofarabine 13venetoclax 12Melphalan 12Antilymphocyte Serum 12Mycophenolic Acid 11Methotrexate 11Radiotherapy 10Mitoxantrone 10Daunorubicin 10Busulfan 10sargramostim 9aldesleukin 9Vincristine 9Sirolimus 9Topotecan 8Idarubicin 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia × Carmustine × Clear all
NCT00477035 2017-01-11

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Stanford University

Phase 1 Completed
22 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡